Evaluation of Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and Their Tissue Inhibitors (TIMP-1 and TIMP-2) in Plasma from Patients with Neurodegenerative Dementia

Investigation of Matrix Metalloproteinases, MMP-2 and MMP-9, in Plasma Reveals a Decrease of MMP-2 in Alzheimer's Disease

(2018) Nastasia K.-H. Lim et al.   JOURNAL OF ALZHEIMERS DISEASE

A novel network analysis approach reveals DNA damage, oxidative stress and calcium/cAMP homeostasis-associated biomarkers in frontotemporal dementia

(2017) Fernando Palluzzi et al.   PLoS One

Plasma β-amyloid in Alzheimer’s disease and vascular disease

(2016) Shorena Janelidze et al.   Scientific Reports

Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases

(2015) Marjana Brkic et al.   MEDIATORS OF INFLAMMATION

A 1-42-RAGE Interaction Disrupts Tight Junctions of the Blood-Brain Barrier Via Ca2+-Calcineurin Signaling

(2012) S.-Y. Kook et al.   JOURNAL OF NEUROSCIENCE

Regulation of matrix metalloproteinase 2 by oligomeric amyloid β protein

(2011) Wenjun Li et al.   BRAIN RESEARCH

Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease

(2010) Solveig Horstmann et al.   INTERNATIONAL PSYCHOGERIATRICS

Matrix Metalloprotease-9 Inhibition Improves Amyloid  -Mediated Cognitive Impairment and Neurotoxicity in Mice

(2009) H. Mizoguchi et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Matrix metalloproteinases-2 and -3 are reduced in cerebrospinal fluid with low beta-amyloid1–42 levels

(2009) Reinhilde Mlekusch et al.   NEUROSCIENCE LETTERS